切换至 "中华医学电子期刊资源库"
高级检索
中华临床实验室管理电子杂志

中华临床实验室管理电子杂志 ›› 2021, Vol. 09 ›› Issue (03) : 150 -153. doi: 10.3877/cma.j.issn.2095-5820.2021.03.005

实验研究

FOXA1在非小细胞肺癌组织中的表达及与癌转移相关性研究
薛兴阳1,†(), 蓝永权2, 丁丹丹1, 吴华振3, 罗志明1, 赵健1   
  1. 1. 510095　广东广州，广州医科大学附属肿瘤医院
    2. 510095　广东广州，广州医科大学附属肿瘤医院；514000　广东梅州，梅州市人民医院
    3. 510095　广东广州，广州医科大学附属肿瘤医院；511518　广东清远；清远市人民医院
  • 收稿日期:2021-02-27 出版日期:2021-08-26
  • 通信作者: 薛兴阳
  • 基金资助:
    广东省医学科研基金立项项目(A2015514); 广州市医药卫生科技一般引导项目(20151A011089)

FOXA1 expression in non-small cell lung cancer and its correlation with metastasis

Xingyang Xue1,†(), Yongquan Lan2, Dandan Ding1, Huazhen Wu3, Zhiming Luo1, Jian Zhao1   

  1. 1. Department of Thoracic Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Guangdong 510095, China
    2. Department of Thoracic Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Guangdong 510095, China; Department of Chemotherapy, Meizhou People's Hospital, Meizhou Guangdong 514000, China
    3. Department of Thoracic Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Guangdong 510095, China; Department of Oncology Radiotherapy, The Sixth Affiliated Hospital of Guangzhou Medical University/Qingyuan People's Hospital, Qingyuan Guangdong 511518, China
  • Received:2021-02-27 Published:2021-08-26
  • Corresponding author: Xingyang Xue
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

薛兴阳, 蓝永权, 丁丹丹, 吴华振, 罗志明, 赵健. FOXA1在非小细胞肺癌组织中的表达及与癌转移相关性研究[J/OL]. 中华临床实验室管理电子杂志, 2021, 09(03): 150-153.

Xingyang Xue, Yongquan Lan, Dandan Ding, Huazhen Wu, Zhiming Luo, Jian Zhao. FOXA1 expression in non-small cell lung cancer and its correlation with metastasis[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2021, 09(03): 150-153.

目的

探讨转录因子FOXA1在非小细胞肺癌的原发灶及转移灶中的表达情况及其与非小细胞肺癌转移的相关性。

方法

随机收集广州医科大学附属肿瘤医院2011年9月至2016年12月非小细胞肺癌病理确诊病例，包括非匹配的40例原发灶与40例转移灶组织标本、40例Ⅰ期及40例Ⅳ期患者原发灶组织标本，免疫组化法检测FOXA1表达及比较其在不同组织的差异情况。分析其中的12例既有原发灶又有转移灶的Ⅳ期非小细胞肺癌组织标本，比较FOXA1在同一病人原发灶和转移灶的表达差异情况。

结果

FOXA1主要表达于肿瘤细胞核，细胞质及胞膜无明显表达。在转移灶组织中FOXA1表达水平明显高于原发灶肺癌组织 (P＜0.05)。在Ⅳ期肺癌组织中FOXA1表达水平明显高于Ⅰ期肺癌组织 (P＜0.05)。在12例同一非小细胞肺癌病人原发灶及转移灶组织中，FOXA1在转移灶中表达高于原发灶，但P值未达到统计学意义。

结论

FOXA1与非小细胞肺癌转移可能相关，有望成为新的非小细胞肺癌治疗靶点。

关键词: FOXA1, 非小细胞肺癌, 免疫组织化学, 转移
Objective

To investigate the expression of FOXA1 in primary and metastatic non-small cell lung cancer (NSCLC) and its correlation with metastasis.

Methods

Patients with pathologically confirmed NSCLC from The Affiliated Cancer Hospital & Institute of Guangzhou Medical University from September 2011 to December 2016 were randomly collected, including mismatched tissue samples from 40 primary lesions and 40 metastatic lesions, and tissue samples from 40 stage Ⅰ and 40 stage Ⅳ patients. The expression of FOXA1 was detected by immunohistochemistry and the difference in different tissues was compared. The expression of FOXA1 in 12 cases of stage Ⅳ non-small cell lung cancer with both primary and metastatic tissues was analyzed.

Results

FOXA1 was mainly expressed in the nucleus, but not in the cytoplasm and membrane. In 40 pairs of lung cancer tissues and metastatic tissues, the expression level of FOXA1 in metastatic tissues was significantly higher than that in lung cancer tissues (P＜0.05). The expression level of FOXA1 in stage Ⅳ lung cancer tissue was significantly higher than that in stage Ⅰ lung cancer tissue (P＜0.05). The expression level of FOXA1 in primary and metastatic foci of 12 patients with NSCLC was different. The expression level of FOXA1 in metastatic foci was higher than that in primary foci, but the P value was not statistically significant.

Conclusion

FOXA1 may be related to the metastasis of NSCLC and is expected to become a new therapeutic target for NSCLC.

Key words: FOXA1, Non-small cell lung cancer, Immunohistochemistry, Metastasis
表1 NSCLC非匹配患者不同病灶中FOXA1表达情况(例)
项目 FOXA1表达 χ2 P 值
低 高
非匹配患者的肺癌组织 33 7 13.653 0.000
非匹配患者的转移灶组织 17 23
表2 FOXA1在NSCLC Ⅰ期及Ⅳ期肺癌原发灶组织中的表达情况(例)
项目 FOXA1表达 χ2 P 值
低 高
Ⅰ期肺癌组织 33 7 4.013 0.045
Ⅳ期肺癌组织 25 15
图1 FOXA1在病例52332中肺癌原发灶(上)及脑转移灶(下)中的表达情况
1
Bray F, Ferlay J, Soerjomataram I, et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
2
Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(3): 145-164.
3
Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments[J]. Lancet, 2017, 389(10066): 299-311.
4
Zhu T, Bao X, Chen M, et al. Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis[J]. Front Oncol, 2020, 10: 585284.
5
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
6
Brix DM, Bundgaard Clemmensen KK, Kallunki T. Zinc Finger Transcription Factor MZF1-A Specific Regulator of Cancer Invasion[J]. Cells, 2020, 9(1): 223.
7
Parolia A, Cieslik M, Chu SC, et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer[J]. Nature, 2019, 571(7765): 413-418.
8
Huang C, Liu J, Xiong B, et al. Expression and prognosis analyses of forkhead box A (FOXA) family in human lung cancer[J]. Gene, 2019, 685: 202-210.
9
Adams EJ, Karthaus WR, Hoover E, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes[J]. Nature, 2019, 571(7765): 408-412.
10
Cocce KJ, Jasper JS, Desautels TK, et al. The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer[J]. Cell reports, 2019, 29(4):889-903.e810.
11
Liu B, Qin J, Shen W, et al. FOXA1 promotes proliferation, migration and invasion by transcriptional activating KRT7 in human gastric cancer cells.[J] J Biol Regul Homeost Agents, 2019, 33(4):1041-1050.
12
Katoh M, Katoh M. Human FOX gene family (Review)[J]. Int J Oncol, 2004, 25(5):1495-500.
13
Nakshatri H, Badve S. FOXA1 in breast cancer[J]. Expert Rev Mol Med, 2009, 11:e8.
14
Cirillo LA, Lin FR, Cuesta I, et al. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4[J]. Mol Cell, 2002, 9(2): 279-89.
15
Watanabe H, Francis JM, Woo MS, et al. Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target[J]. Genes Dev, 2013, 27(2): 197–210.
16
Lin L, Miller CT, Contreras JI, et al. The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas[J]. Cancer Res, 2002, 62(18): 5273-5279.
17
Wang H, Meyer CA, Fei T, et al. A systematic approach identifies FOXA1 as a key factor in the loss of epithelial traits during the epithelial-to-mesenchymal transition in lung cancer[J]. BMC Genomics, 2013, 14: 680.
18
Deutsch L, Wrage M, Koops S, et al. Opposite roles of FOXA1 and NKX2-1 in lung cancer progression[J]. Genes Chromosomes Cancer, 2012, 51(6): 618-29.
19
Li J, Zhang S, Zhu L, et al. Role of transcription factor FOXA1 in nonsmall cell lung cancer[J]. Mol Med Rep, 2018, 17(1): 509-521.
20
Du H, Chen Y, Hou X, et al. PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC[J]. Cell Death Dis, 2017, 8(10): e3143.
21
Ye JJ, Cheng YL, Deng JJ, et al. LncRNA LINC00460 promotes tumor growth of human lung adenocarcinoma by targeting miR-302c-5p/FOXA1 axis[J]. Gene, 2019, 685: 76-84.
[1] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[2] 王真真, 谢佳翊, 余涵, 沈雪. 隐匿性乳腺癌子宫转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 317-319.
[3] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[4] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[6] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[7] 韩婧, 郝少龙, 康骅. 北京市单中心甲状腺癌患者临床特征的回顾分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 490-493.
[8] 林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊（第15期）——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
[9] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[10] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[11] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[12] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[13] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[14] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[15] 王曦娅, 尹弘青, 丁伟, 徐滨, 于海源, 马东升, 邵军. 桥本背景下甲状腺乳头状癌多参数分析预测大容量淋巴结转移[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 548-554.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号